HBx hijacks the miR-19a-3p/BAMBI/TGF-β1 axis to impair the anti-tumour activity of CD4+ T cells in diffuse large B-cell lymphoma – Research

Background:

Hepatitis B virus (HBV) is clinically associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL), while cellular communication in the tumour microenvironment (TME) is recognized as a critical driver of tumour progression. Nevertheless, whether HBV infection mediates DLBCL cell-immune cell crosstalk remains undefined, with the precise mechanisms and associated key molecules remaining elusive.

Methods:

SsGSEA, Cox regression (univariate/multivariate), WGCNA, and Kaplan-Meier analyses identified prognostic immune subsets and miRNAs in HBV⁺ DLBCL. Dual luciferase assay, qRT-PCR, western blot, ChIP, Co-IP, flow cytometry, enzyme-linked immunosorbent assay, immunohistochemistry, and murine models were employed together to evaluate CD4⁺ T cell dysfunction in vitro and in vivo. ScRNA-seq analyses encompassed clustering, pseudotemporal trajectory, and ligand-receptor networks to decode TME dynamics.

Results:

TME profiling identified diminished CD4⁺ T cell infiltration as an independent predictor of poor survival in HBV⁺ DLBCL. Mechanistically, HBx-mediated down-regulation of miR-19a-3p activated the BAMBI/Wnt signalling pathway, thereby enhancing TGF-β1 secretion and suppressing the anti-tumour activity of CD4⁺ T cells. Single-cell analysis revealed that BAMBI^high DLBCL cells engage CD4⁺ T cells via TGFB1-TGFBR2 pair, with TGFBR2 enriched in exhausted subsets of CD4⁺ T cells and shaping their dysfunctional fate. Therapeutic restoration of miR-19a-3p or blockade of TGF-β reinforced the CD4⁺ T cell anti-tumour activity and restrained the progression of HBx-overexpressing DLBCL in vivo.

Conclusions:

HBx promoted TGF-β1 hypersecretion via miR-19a-3p repression-mediated Wnt/β-catenin activation, directly driving CD4⁺ T cell depletion and functional exhaustion in DLBCL. Our work provided important insights into the immune determinants of poor prognosis in HBV⁺ DLBCL, highlighting the pivotal role of CD4⁺ T cell dysfunction in driving disease progression and adverse clinical outcomes.

Highlights:

Reduced CD4⁺ T cell enrichment in the TME predicted poor survival in HBV⁺ DLBCL. Down-regulation of miR-19a-3p by HBx activated the BAMBI-mediated Wnt signalling, amplifying TGF-β1 secretion to suppress anti-tumour activity of CD4⁺ T cells. The TGF-B1/TGFBR2 pair mediated the HBV⁺ DLBCL-CD4⁺ T cell communication. Targeting TGF-β or miR-19a-3p improved CD4⁺ T cell immunity to suppress HBV⁺ DLBCL progression.